NCT05781698

Repurposing Fenofibrate in Modulating mTOR/NLRP3 Inflammasome in Patients With Ulcerative Colitis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: Tanta University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Fibrates, specific pharmacological agonists of PPARα, have been widely used to treat hypercholesterolemia and hypertriglyceridemia. Apart from their metabolic action, anti-inflammatory properties of fibrates have been described, including inhibition of NF-kappa B signaling and pro-inflammatory cytokine production. 4 Fenofibrate, an important peroxisome proliferator-activated receptor-a (PPAR- α) agonist, is widely used in clinical as a triglyceride (TG)-lowering agent

Conditions

• Inflammatory Bowel Diseases

Interventions

Type	Name	Description
DRUG	Mesalamine	mesalamine is the cornerstone used for the treatment of mild to moderate ulcerative colitis
DRUG	Fenofibrate	Fibrates, which are specific pharmacological agonists of PPARα, have been widely used in the treatment for hypercholesterolemia and hypertriglyceridemia

Timeline

• Start date: 2023-03-20
• Primary completion: 2024-10-20
• Completion: 2024-12-20
• First posted: 2023-03-23
• Last updated: 2025-04-06

Locations

1 site across 1 country: Egypt